Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Occurrence of Dysgeusia in Patients Being Treated for Cancer.
Di Meglio J, Dinu M, Doni L, Rossi G, Giorgione R, Colombini B, Antonuzzo L, Sofi F. Di Meglio J, et al. Among authors: doni l. Nutr Cancer. 2022;74(8):2868-2874. doi: 10.1080/01635581.2022.2042569. Epub 2022 Feb 23. Nutr Cancer. 2022. PMID: 35196919
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Roviello G, et al. Among authors: doni l. Cancer Med. 2022 Aug;11(16):3084-3092. doi: 10.1002/cam4.4681. Epub 2022 Mar 20. Cancer Med. 2022. PMID: 35312175 Free PMC article.
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors.
Roviello G, Catalano M, De Giorgi U, Maruzzo M, Buti S, Gambale E, Procopio G, Ottanelli C, Caliman E, Isella L, Sepe P, Brighi N, Santoni M, Galli L, Conca R, Doni L, Antonuzzo L. Roviello G, et al. Among authors: doni l. Front Oncol. 2022 Aug 16;12:918413. doi: 10.3389/fonc.2022.918413. eCollection 2022. Front Oncol. 2022. PMID: 36052244 Free PMC article.
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma.
Catalano M, De Giorgi U, Maruzzo M, Bimbatti D, Buti S, Mazzaschi G, Procopio G, Santoni M, Galli L, Conca R, Doni L, Antonuzzo L, Roviello G. Catalano M, et al. Among authors: doni l. Biomedicines. 2022 Sep 30;10(10):2444. doi: 10.3390/biomedicines10102444. Biomedicines. 2022. PMID: 36289706 Free PMC article.
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V, De Giorgi U, Bimbatti D, Nolè F, Carrozza F, Buti S, Iacovelli R, Ciccarese C, Masini C, Baldessari C, Doni L, Cusmai A, Gernone A, Scagliarini S, Pignata S, de Braud F, Verzoni E. Procopio G, et al. Among authors: doni l. Tumori. 2023 Feb;109(1):129-137. doi: 10.1177/03008916221138881. Epub 2022 Nov 29. Tumori. 2023. PMID: 36447337 Free PMC article. Clinical Trial.
Gender and cystectomy for bladder cancer: A high-volume tertiary urologic care center experience.
Mariotti A, Spatafora P, Sessa F, Saieva C, Galli IC, Roviello G, Doni L, Zaccaro C, Bisegna C, Conte FL, Mariottini R, Marzocco A, Masieri L, Vignolini G, Minervini A, Serni S, Carini M, Nesi G, Villari D. Mariotti A, et al. Among authors: doni l. Eur J Surg Oncol. 2023 Oct;49(10):107034. doi: 10.1016/j.ejso.2023.107034. Epub 2023 Aug 18. Eur J Surg Oncol. 2023. PMID: 37639860 Free article.
81 results